Journal of Immunology Research

Review Article

Meningococcal Antigen Typing System Development and Application to the Evaluation of Effectiveness of Meningococcal B Vaccine and Possible Use for Other Purposes

Table 2

Relative contribution (%) of all possible antigen combinations to MATS-predicted coverage in three countries [5, 30, 32, 33].
Antigen (MATS phenotype)England and Wales
( = 535)		Canada
( = 157)		Greece
( = 148)
fHbp+/NHBA−/NadA−/PorA−14.612.79.5
fHbp−/NHBA+/NadA−/PorA−7.913.433.8
fHbp−/NHBA−/NadA+/PorA−——0.7
fHbp−/NHBA−/NadA−/PorA+0.4—0.7
fHbp+/NHBA+/NadA−/PorA−29.925.537.1
fHbp+/NHBA−/NadA+/PorA−—0.6—
fHbp+/NHBA−/NadA−/PorA+3.21.9—
fHbp−/NHBA+/NadA−/PorA+0.9—1.3
fHbp−/NHBA+/NadA+/PorA−0.40.6—
fHbp−/NHBA−/NadA+/PorA+———
fHbp+/NHBA+/NadA+/PorA−0.2——
fHbp+/NHBA+/NadA−/PorA+15.711.56.1
fHbp+/NHBA−/NadA+/PorA+———
fHbp−/NHBA+/NadA+/PorA+———
fHbp+/NHBA+/NadA+/PorA+———
fHbp−/NHBA−/NadA−/PorA−26.933.810.8